A randomised evaluation of low‐dose Ara‐ <scp>C</scp> plus pegylated recombinant arginase <scp>BCT</scp> ‐100 versus low dose Ara‐ <scp>C</scp> in older unfit patients with acute myeloid leukaemia: Results from the <scp>LI</scp> ‐1 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A randomised evaluation of low‐dose Ara‐ C plus pegylated recombinant arginase BCT ‐100 versus low dose Ara‐ C in older unfit patients with acute myeloid leukaemia: Results from the LI ‐1 trial

Published:2022-11-22 Issue:5 Volume:200 Page:573-578
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Mussai Francis¹^ORCID,De Santo Carmela¹,Cheng Paul²,Thomas Ian F.³,Ariti Cono³,Upton Laura³,Scarpa Ugo¹,Stavrou Victoria¹,Sydenham Mia³,Burnett Alan K.⁴,Knapper Steven K.³,Mehta Priyanka⁵,McMullin Mary F.⁶^ORCID,Copland Mhairi³^ORCID,Russell Nigel H.⁷^ORCID,Dennis Mike⁸^ORCID

Affiliation:

1. Institute of Immunology and Immunotherapy University of Birmingham Birmingham UK

2. Bio‐Cancer Treatment International Hong Kong City Hong Kong

3. Centre for Trials Research Cardiff University Cardiff UK

4. Paul O'Gorman Leukaemia Research Centre, School of Cancer Sciences University of Glasgow Glasgow UK

5. University Hospitals Bristol Bristol UK

6. Queen's University Belfast UK

7. Guy's Hospital London UK

8. The Christie Manchester UK

Funder

Blood Cancer UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18560

Reference16 articles.

1. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

2. A randomised evaluation of low‐dose cytosine arabinoside (ara‐C) plus tosedostat versus low‐dose ara‐C in older patients with acute myeloid leukaemia: results of the LI‐1 trial

3. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

4. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

5. Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dysregulated arginine metabolism in precursor B-cell acute lymphoblastic leukemia in children: a metabolomic study;BMC Pediatrics;2024-08-22

2. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules;Cancer Letters;2024-06

3. Metabolic instruction of the graft-versus-leukemia immunity;Frontiers in Immunology;2024-03-04

4. PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults;Frontiers in Oncology;2024-01-31

5. The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways;Cell Communication and Signaling;2023-09-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3